Aetna Will Leave Iowa’s ACA Exchanges
This week, Aetna announced it will not offer plans on Iowa’s Affordable Care Act (ACA) exchange in 2018. According to The Washington Post, the company cited financial risk, as well as uncertainty surrounding the future of the marketplace, as reasons for its decision. The announcement follows a decision earlier in the week from Wellmark Blue Cross and Blue Shield to also stop selling on the Iowa marketplace next year. As a result, the majority of the state’s counties will only have 1 insurer.
Cigna Reports Drop in Opioid Use
In the last 12 months, Cigna has cut prescription opioid use among customers by nearly 12%. The company has pledged to cut prescriptions of opioids by 25% by 2019, reported Reuters. Cigna is keeping physicians informed of opioid prescriptions in order to detect potential misuse by individuals and inform physicians of their own prescribing patterns. Another way Cigna has sought to combat the opioid epidemic is by removing a policy that required doctors to seek authorization in order to treat addicts.
A $15B Addition to GOP Health Bill
The Republican healthcare bill may not be completely dead. GOP leaders have been working with the House Freedom Caucus and the White House to try to revive the bill with changes, according to The New York Times. House Speaker Paul Ryan (R-Wisconsin) has negotiated the addition of a $15 billion fund to create a risk-sharing program to help insurers pay for their sickest customers and lower premiums. The proposal would prevent patients with high-cost diseases from being placed into a separate high-risk insurance pool.
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
EMBARK Data Show Continued Improvements With DMD Gene Therapy
March 19th 2025Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that benefits in functional outcomes, gene expression, and muscle imaging persist 2 years after receiving the gene therapy.
Read More